Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Vaccine Adjuvants. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113527382B reveals a novel MPLA synthesis route using Nap protection. Achieve higher purity and cost reduction in vaccine adjuvant manufacturing with scalable methods.
Patent CN113527050B reveals a novel Nap-protected MPLA intermediate synthesis. This method eliminates hydrogenation, ensuring high purity and scalable supply for vaccine adjuvant manufacturing.